BridgeMD
New treatment option for Coronary Artery Ectasia
Official title Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia
ClinicalTrials.gov ID: NCT07511257
What this study is testing
What is Aspirin 100 mg?
Aspirin 100 mg is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for coronary artery ectasia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Coronary artery ectasia (CAE) is a condition in which a coronary artery becomes abnormally dilated, measuring at least 50% larger than the adjacent normal segment. Although relatively uncommon, CAE is clinically important because it can lead to abnormal blood flow and increase the risk of blood clot formation.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Adults aged 18 to 80 years, of either sex, hospitalized with acute coronary syndrome (ACS) with or without ST-segment elevation.
- Recent ACS within 7 days prior to enrollment, defined by all of the following:
- Clinical presentation consistent with acute coronary syndrome.
- Elevated high-sensitivity cardiac troponin above the 99th percentile.
- Presence or absence of persistent ST-segment elevation.
You likely can't join if
- Pregnant women.
- Current indication for temporary or long-term anticoagulation therapy at the time of enrollment.
- Severe chronic kidney disease, defined as KDIGO stage G4 or higher (estimated glomerular filtration rate [eGFR] \<30 mL/min/1.73 m²).
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² at hospital discharge.
- History of major bleeding, active bleeding, or high bleeding risk, including but not limited to gastrointestinal bleeding, intracranial hemorrhage...
- Advanced heart failure, defined as left ventricular ejection fraction (LVEF) \<30% plus at least one of the following:
See the full eligibility criteria
- Adults aged 18 to 80 years, of either sex, hospitalized with acute coronary syndrome (ACS) with or without ST-segment elevation.
- Recent ACS within 7 days prior to enrollment, defined by all of the following:
- Clinical presentation consistent with acute coronary syndrome.
- Elevated high-sensitivity cardiac troponin above the 99th percentile.
- Presence or absence of persistent ST-segment elevation.
- Coronary artery ectasia in the culprit coronary artery, defined by all of the following:
- The presence of ectasia will be determined by agreement of two expert treatment cardiologists, and will be confirmed by quantitative coronary angiography (QCA).
- Identification of a culprit artery consistent with the electrocardiographic territory involved (in cases with ST-segment elevation) or with angiographic features suggestive of an atherothrombotic event, such as the...
- Hospital admission lasting more than 24 hours.
- Management with either percutaneous coronary intervention or medical therapy, as determined by the treating medical team. Intracoronary interventions such as stent implantation, balloon angioplasty, or thrombus...
- Ability and willingness to provide written informed consent and to participate in the study.
- Pregnant women.
- Current indication for temporary or long-term anticoagulation therapy at the time of enrollment.
- Severe chronic kidney disease, defined as KDIGO stage G4 or higher (estimated glomerular filtration rate [eGFR] \<30 mL/min/1.73 m²).
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² at hospital discharge.
- History of major bleeding, active bleeding, or high bleeding risk, including but not limited to gastrointestinal bleeding, intracranial hemorrhage, or other conditions considered by the treating physician to confer a...
- Advanced heart failure, defined as left ventricular ejection fraction (LVEF) \<30% plus at least one of the following:
- More than two hospitalizations or unplanned emergency department visits for heart failure in the past year, or
- NYHA functional class III or IV symptoms despite optimal medical therapy at enrollment or within the previous 3 months.
The study team makes the final eligibility decision.
Where it's taking place
- Mexico City, Tlalpan, Mexico
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico City, Tlalpan, Mexico. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.